Previous 10 | Next 10 |
2023-04-02 08:49:17 ET Summary Shares of gene therapy concern Voyager Therapeutics, Inc. have moved up more than 25% in 2023 on a couple of licensing deals. Last month, Novartis exercised an option to license Voyager's novel capsids for use in gene therapy programs against two und...
2023-03-31 09:24:34 ET A committee of the European Medicines Agency (EMA) recommended expanding the approval of Novartis' ( NYSE: NVS ) Entresto to include children and adolescents with heart failure, and in two new strengths. The EMA's Committee for Medicinal Products for...
2023-03-30 10:30:00 ET The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. A select handful of stocks have been immune to this downward trend, however. Most companies with robust...
2023-03-30 09:03:39 ET Cancer-focused biotech Erasca ( NASDAQ: ERAS ) extended gains in the pre-market Thursday after Mizhuho Securities initiated its coverage with a Buy rating and a $9 per share target, citing its upcoming data readouts and liquidity position. “We l...
2023-03-30 05:13:16 ET The United Nations-backed Medicines Patent Pool (MPP) signed agreements with Aurobindo, Cipla and Viatris ( NASDAQ: VTRS ) to produce generic versions of ViiV Healthcare's long-acting HIV prevention medicine. ViiV — which is majority o...
2023-03-29 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-29 15:05:26 ET Summary This portfolio uses historical performance and qualitative business traits to determine low-risk assets. These assets are leading their class and represent sectors that offer lower volatility. Backtesting proves that the constituents outperform t...
2023-03-29 13:31:06 ET Cancer-focused biotech Erasca ( NASDAQ: ERAS ) added ~8% on Wednesday, recording the biggest intraday gain since January after its Chief Executive and Chairman Jonathan Lim disclosed the purchase of 100K company shares. According to a regulatory ...
2023-03-27 17:07:01 ET Novartis ( NYSE: NVS ) closed up 8% on Monday after reporting positive top-line data on its breast cancer drug Kisqali (ribociclib) in those with earlier stages of the disease. Results showed Kisqali significantly reduced the risk of disease re...
2023-03-27 15:26:39 ET Deutsche Bank has upgraded Novartis ( NYSE: NVS ) to hold from sell saying that positive top-line results of a phase 3 trial of its breast cancer drug Kisqali (ribociclib) released earlier Monday were a surprise. The firm has a price target of CH...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...